Butterfly Network, Inc. develops semiconductor-based ultrasound devices, programmable cloud software and AI for medical imaging and sensing. Its Ultrasound-on-Chip technology underpins handheld whole-body ultrasound systems such as Butterfly iQ, iQ+ and iQ3, along with enterprise workflow software including Compass AI and developer tools such as Butterfly Garden.
Company news commonly covers financial results, point-of-care ultrasound adoption, FDA-cleared AI tools such as its Gestational Age Tool, U.S. and international sales channels, and platform initiatives. Updates also address Butterfly Embedded, the company’s licensing and co-development effort for applying its ultrasound chip and software platform in partner-built products, as well as board and leadership changes tied to medtech, clinical strategy and commercialization.
Butterfly Network (NYSE: BFLY) received FDA clearance for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound and app. The AI-powered blind-sweep tool estimates gestational age in under two minutes for 16–37 weeks, trained on >21 million images and deployed in Malawi and Uganda.
The clearance positions Butterfly to expand maternal-health access in low-resource settings and rural U.S. communities, supported in part by a Gates Foundation grant.
Butterfly Network (NYSE: BFLY) appointed David Horsley, Ph.D., as Senior Vice President, Innovation — Butterfly Embedded on March 10, 2026. He will lead strategy, product development, partnerships and commercialization for the Ultrasound-on-Chip™ co-development and licensing initiative. The program aims to embed Butterfly’s semiconductor ultrasound into new products; the company reports a growing pipeline and early collaborations that are contributing revenue.
Dr. Horsley brings MEMS and ultrasonic sensor commercialization experience, including co-founding Chirp Microsystems and prior roles at TDK, Hewlett Packard Laboratories, Northeastern University, and UC Berkeley.
Butterfly Network (NYSE: BFLY) reported record Q4 2025 revenue of $31.5M (41% YoY) and positive operating cash flow in Q4, driving the lowest annual cash usage in company history. The Midjourney partnership contributed $6.8M of Q4 revenue and up to $74M over five years.
GAAP gross margin rose to 67.3%, net loss narrowed to $15.3M, cash and equivalents were $150.5M, and 2026 guidance targets revenue of $117M–$121M with adjusted EBITDA loss of $21M–$25M.
Butterfly Network (NYSE: BFLY) will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The company presentation is scheduled for 11:50 AM ET, with senior management hosting one-on-one investor meetings.
Presenters include Joseph DeVivo (President, CEO & Chairman), John Doherty (EVP, CFO) and Megan Carlson (SVP, Accounting & Finance). A webcast will be available in the Events & Presentations section of Butterfly’s investor website.
Butterfly Network (NYSE: BFLY) announced GovRAMP and TX-RAMP authorizations for its Butterfly iQ+/iQ3 probes and Compass AI™ cloud workflow, enabling sales to all state and local government agencies including Texas.
The solution completed a third-party assessment by A-LIGN and a GovRAMP PMO quality review; Butterfly is pursuing FedRAMP in 2026 and additional certifications.
Butterfly Network (NYSE: BFLY) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 at 8:00 AM ET.
Joseph DeVivo, President and CEO, and John Doherty, EVP and CFO, will host a pre-market conference call and webcast to discuss financial performance and operational progress. The live webcast will be archived and a telephone replay is available through March 5, 2026.
Butterfly Network (NYSE: BFLY) said it expects fourth-quarter 2025 revenue growth of at least 17% year-over-year. The company described momentum in its handheld ultrasound business and highlighted plans to expand co-development and chip licensing opportunities, calling 2026 a potential inflection year. Butterfly will present a business update at the 44th J.P. Morgan Healthcare Conference on January 15, 2026 at 9:00 AM PST. The company said audited fourth-quarter and full-year 2025 results and 2026 guidance are expected in late February 2026. A webcast of the JP Morgan presentation will be available for replay through February 15, 2026.
Butterfly Network (NYSE: BFLY) announced a planned Beam Steering API release expected in first half of 2026 to allow third-party developers in Butterfly Garden and Ultrasound-on-Chip co-development programs to access its electronically steered 3D imaging capabilities.
The API exposes software-defined beam steering features (including off-axis beam tilt up to 20 degrees) previously reserved for Butterfly apps and is built on a semiconductor CMUT array with approximately 9,000 elements. The SDK is expected to support a subset of presets across abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Availability and technical scope depend on ongoing development, regulatory considerations, and partner agreements.
Butterfly Network (NYSE: BFLY) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026 at 9:00 AM PST. Company executives Joseph DeVivo, John Doherty, and Megan Carlson will host investor meetings and deliver the presentation.
A webcast will be posted in the company's Events & Presentations investor section and will be available for replay through February 15, 2026. Investors may schedule one-on-one meetings via company contacts or through J.P. Morgan representatives.
Butterfly Network (NYSE: BFLY) will participate at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 2, 2025. Joseph DeVivo, President, CEO & Chairman, and Megan Carlson, Senior VP & Interim CFO, will take part in a fireside chat at 1:20 PM ET and will host one-on-one investor meetings.
A live webcast of the fireside chat will be available in the Events & Presentations section of the Butterfly investor website and will be available for replay after the event. One-on-one meetings can be scheduled through Evercore representatives.